Oct 5, 2026 08:45AM
Sep 30, 2026 05:15PM
Sep 30, 2026 05:15PM
Sep 29, 2026 07:05AM
Sep 29, 2026 07:05AM
Sep 29, 2026 07:02AM
Sep 29, 2026 07:00AM Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Po
Aug 4, 2026 09:15AM
May 22, 2026 05:15PM
May 22, 2026 05:15PM
May 21, 2026 06:30AM
May 21, 2026 06:30AM
May 21, 2026 06:02AM
May 21, 2026 06:00AM Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Apr 9, 2026 08:45AM
Mar 30, 2026 08:47AM
Mar 30, 2026 08:45AM
Mar 25, 2026 04:44AM
Mar 3, 2026 08:45AM
Jan 28, 2026 08:45AM
Jan 28, 2026 08:45AM Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Dec 9, 2025 05:45PM
Dec 9, 2025 05:45PM
Dec 7, 2025 06:20PM
Dec 7, 2025 06:20PM
Dec 7, 2025 06:15PM
Dec 7, 2025 06:15PM
Nov 12, 2025 08:45AM Immix Biopharma names Michael Grabow chief commercial officer
Nov 12, 2025 08:45AM
Nov 3, 2025 08:45AM
Nov 3, 2025 08:45AM
Nov 3, 2025 08:45AM
Nov 3, 2025 08:45AM
Oct 14, 2025 08:45AM
Oct 6, 2025 04:05PM Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
Oct 1, 2025 08:45AM
Sep 18, 2025 01:30PM
Sep 18, 2025 01:30PM
Sep 11, 2025 09:15AM
Sep 11, 2025 09:15AM
Sep 8, 2025 04:05PM
Sep 8, 2025 04:05PM Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Aug 25, 2025 09:30AM
Aug 6, 2025 12:31PM
Aug 6, 2025 12:30PM
Jul 11, 2025 09:36AM
Jul 11, 2025 09:36AM
Jul 8, 2025 06:51AM
Jul 7, 2025 09:35AM Immix Biopharma expands trial sites for AL amyloidosis cell therapy
Jul 7, 2025 09:35AM

334,268 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All